Could a lower dose of cyclophosphamide make stem cell transplants less risky?
NCT ID NCT03983850
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can reduce side effects while still preventing the donor cells from attacking the recipient's body. The trial includes 105 people aged 15-65 with blood cancers like leukemia or lymphoma, along with their healthy donors. Participants receive chemotherapy, a stem cell transplant, and the lower-dose drug, with researchers monitoring for complications over five years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cyclophosphamide
What this could lead to
If successful, this could lead to safer stem cell transplants with fewer severe side effects for people with blood cancers.
What could go wrong
This is an early-phase trial with only 105 participants, so results may not apply to everyone. Lowering the dose might also reduce its effectiveness in preventing graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States